A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3

PURPOSE: NCIC Clinical Trials Group PA.3 was a randomized control trial that demonstrated improved overall survival (OS) in patients receiving erlotinib in addition to gemcitabine for locally advanced or metastatic pancreatic cancer. Prior to therapy, patients had plasma samples drawn for future stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shultz, David B., Pai, Jonathan, Chiu, Wayland, Ng, Kendall, Hellendag, Madeline G., Heestand, Gregory, Chang, Daniel T., Tu, Dongsheng, Moore, Malcolm J., Parulekar, Wendy R., Koong, Albert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725948/
https://www.ncbi.nlm.nih.gov/pubmed/26808546
http://dx.doi.org/10.1371/journal.pone.0147995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725948/
https://www.ncbi.nlm.nih.gov/pubmed/26808546
http://dx.doi.org/10.1371/journal.pone.0147995

Ejemplares similares